Gyre Therapeutics Inc ( (GYRE) ) has released its Q1 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Gyre Therapeutics Inc., a biotechnology company focused on organ fibrosis, reported its first quarter 2025 financial results, highlighting its strategic advancements in the liver and oncology supportive care spaces. The company posted a net income of $3.7 million and reaffirmed its full-year revenue guidance of $118–$128 million. Key developments include the completion of data collection for a Phase 3 trial of Hydronidone, the initiation of avatrombopag commercialization in China, and the approval for a new indication of pirfenidone in oncology supportive care. Despite a revenue decline to $22.1 million from $27.2 million in the previous year, Gyre remains optimistic about future growth, driven by new product launches and strategic market expansions. The company holds $51.3 million in cash and equivalents, supporting its operations for the next 12 months. Looking ahead, Gyre anticipates revenue growth through the commercialization of Nintedanib and continued expansion of avatrombopag, maintaining a positive outlook for the remainder of 2025.